Clinical Laserthermia Systems AB OMXSTO:CLS_B:
Q4 NET SALES SEK 830 THOUSAND
Q4 OPERATING LOSS SEK 10,615,000
CONTINUES TO MAINTAIN COMMUNICATED TARGETS FOR 2026
Clinical Laserthermia Systems Says Continues To Maintain Targets For 2026
Earlier from Clinical Laserthermia Systems Ab Class B
- CLS Initiates Recruitment Process For Permanent Chief Financial Officer
- Clinical Laserthermia Systems Q3 Revenue SEK 2.8 Mln
- CLS-sponsored neuro LITT study in patients with malignant brain tumor shows positive results
- Clinical Laserthermia Systems AB: Quarterly Trading Report 2025 Q3